Quantinno Capital Management LP Purchases 17,705 Shares of Tenet Healthcare Corporation $THC

Quantinno Capital Management LP lifted its position in Tenet Healthcare Corporation (NYSE:THC) by 17.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 121,243 shares of the company’s stock after acquiring an additional 17,705 shares during the period. Quantinno Capital Management LP’s holdings in Tenet Healthcare were worth $22,880,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in THC. NewEdge Advisors LLC boosted its position in shares of Tenet Healthcare by 6.1% during the first quarter. NewEdge Advisors LLC now owns 2,890 shares of the company’s stock valued at $389,000 after buying an additional 166 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of Tenet Healthcare by 299.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,700 shares of the company’s stock worth $229,000 after acquiring an additional 1,274 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in Tenet Healthcare during the 2nd quarter valued at $290,000. Quantbot Technologies LP purchased a new stake in Tenet Healthcare in the second quarter worth $65,000. Finally, Amundi boosted its stake in shares of Tenet Healthcare by 4,207.8% during the second quarter. Amundi now owns 27,010 shares of the company’s stock valued at $4,652,000 after purchasing an additional 26,383 shares during the period. 95.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Tenet Healthcare

In other Tenet Healthcare news, EVP Lisa Y. Foo sold 10,000 shares of Tenet Healthcare stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $258.03, for a total value of $2,580,300.00. Following the transaction, the executive vice president owned 32,053 shares in the company, valued at $8,270,635.59. The trade was a 23.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher S. Lynch sold 3,837 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $243.44, for a total transaction of $934,079.28. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $2,329,233.92. The trade was a 28.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,353 shares of company stock valued at $7,683,517 over the last 90 days. Company insiders own 0.97% of the company’s stock.

Tenet Healthcare Price Performance

NYSE THC opened at $254.88 on Friday. The company has a market cap of $21.96 billion, a PE ratio of 9.83, a P/E/G ratio of 0.97 and a beta of 1.27. Tenet Healthcare Corporation has a 52-week low of $156.71 and a 52-week high of $262.68. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. The firm’s 50 day moving average price is $192.10 and its 200-day moving average price is $199.35.

Tenet Healthcare (NYSE:THC) last posted its earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The company had revenue of $6.04 billion during the quarter, compared to analyst estimates of $5.43 billion. During the same quarter in the prior year, the business earned $4.02 earnings per share. Tenet Healthcare’s revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Sell-side analysts forecast that Tenet Healthcare Corporation will post 21.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on THC shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $305.00 price target on shares of Tenet Healthcare in a research note on Tuesday. Barclays raised their target price on shares of Tenet Healthcare from $240.00 to $271.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Morgan Stanley boosted their price target on Tenet Healthcare from $254.00 to $274.00 and gave the company an “overweight” rating in a report on Monday, July 27th. KeyCorp reduced their price objective on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenet Healthcare in a report on Monday, July 27th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Tenet Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $268.50.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.